4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-24-005492
Chief Executive Officer sold 20,000 shares at $62.50 ($1,250,058)
- Chief Executive Officer acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2024-01-16 | Option exercise 10b5-1 | +20,000 | $19.12 | $382,400 | 207,377 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-01-16 | Sale 10b5-1 | −20,000 | $62.50 | $1,250,058 | 187,377 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2024-01-16 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 59,582 | D | ||
| Open-market sales · 20,000 sh · avg $62.50 · $1,250,058 | |||||||
Loading xslF345X05/ownership.xml…